Newscast – Page 106 – media

Pear Therapeutics and Novartis Will Collaborate on Prescription-Strength Apps

Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
- Source: HCANews
- 774
- March 2, 2018
Company Insight digital health mHealth Novartis
Powerful enzyme could make CRISPR gene-editing more versatile

Revamped Cas9 protein could work on more sites in the genome, and with fewer unwanted effects.
- Source: Nature.com
- 568
- March 2, 2018
CRISPR-Cas9 genome editing Researches
Generation Bio Raises $100 Million to Advance Re-Dosable Gene Therapy

Generation Bio said it closed a $100 million series B financing to advance to the clinic its first two therapeutics candidates using its GeneWave platform to develop a new class of genetic medicines with drug-like qualities.
- Source: globalgenes.org
- 509
- March 2, 2018
genetic medicine Market Views Series
Celgene shaken again after the FDA kicks back their marketing application on blockbuster hopeful ozanimod

Celgene has been slammed with a refuse-to-file letter from the FDA for ozanimod, the biggest late-stage drug it has in the pipeline.
- Source: endpts
- 691
- March 2, 2018
Celgene FDA multiple sclerosis ozanimod
Galera Therapeutics Receives FDA Breakthrough Therapy Designation for GC4419 for the Reduction of Severe Oral Mucositis

Designation Based on Positive Results of Phase 2b Trial of GC4419 Severe Oral Mucositis Affects 70 Percent of Head & Neck Cancer Patients Receiving Radiotherapy
- Source: 4-traders
- 474
- March 2, 2018
FDA New Approvals severe oral mucositis SOM
Stem cell therapy offers hope for spinal cord injuries

Scientists have brought the prospect of spinal cord injuries being able to be treated with stem cells one step closer, after research in monkeys showed improvement post-stem cell graft.
- Source: pharmafile
- 428
- March 1, 2018
motor function NPCs Researches
FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor. SYMDEKO is Vertex’s third medicine approved to treat the underlying cause of CF. Vertex is ready to launch SYMDEKO and will begin shipping it to pharmacies in the United States this week.
- Source: finance.yahoo.
- 570
- March 1, 2018
cystic fibrosis FDA New Approvals SYMDEKO™
Viela Bio Spins Out of MedImmune; Raises Up to $250 Million in Series A Financing, 6 Dimensions Capital Leads Investment

Viela Bio announced today that it has incorporated as an independent, inflammation - and autoimmunity - focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca. Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.
- Source: finance.yahoo
- 484
- March 1, 2018
autoimmunity inflammation Market Views
Scandinavian Real Heart selects AdaCore software for artificial heart

Medical technology company Scandinavian Real Heart has announced that it will be using a range of AdaCore software solutions to develop reliable embedded software for its Total Artificial Heart device.
- Source: Verdict Medical Devices
- 602
- March 1, 2018
healthcare technologies and innovations medical device Researches
Cipla Partners With Roche Pharma India To Create Greater Access To Key Medicines

Cipla Ltd. and Roche Products (India) Private Limited have signed a distribution agreement for the promotion and sale of tocilizumab and the 2nd brand of bevacizumab.
- Source: Cipla
- 702
- March 1, 2018
Cipla Company Insight India Roche

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.